Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus Dacarbazine in Metastatic Melanoma
NCT01164007Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2006
- Primary completion
- May 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in Malignant Melanoma (MM), sponsored by Roche. Primary endpoint: Objective Response Rate (CR + PR) up to 6 years. Started Jun 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01164007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01164007.